Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Sales | 10,836,360 | 9,566,900 | 0 | 7,696,900 | 6,508,820 |
| Cost of Goods | 2,082,540 | 1,955,030 | N/A | 1,801,910 | 1,610,280 |
| Gross Profit | 8,753,810 | 7,611,870 | 6,982,460 | 5,894,990 | 4,898,540 |
| Operating Expenses | 5,386,080 | 4,942,680 | 1,547,630 | 4,309,630 | 3,412,520 |
| Operating Income | 3,368,280 | 2,669,220 | -1,547,630 | 1,586,270 | 1,486,300 |
| Other Income | -107,890 | -49,270 | 0 | 432,390 | 53,250 |
| Pre-tax Income | 3,260,390 | 2,619,950 | -1,547,630 | 2,018,660 | 1,539,550 |
| Income Tax | 692,330 | 603,100 | N/A | 450,610 | 455,610 |
| Net Income Continuous | 2,659,946 | 2,013,616 | 1,900,065 | 1,568,048 | 1,085,000 |
| Net Income | $2,568,050 | $2,016,840 | $1,900,065 | $1,568,040 | $1,083,930 |
| EPS Basic Total Ops | 0.45 | 0.34 | 0.31 | 0.25 | 0.17 |
| EPS Basic Continuous Ops | 0.45 | 0.34 | 0.31 | 0.25 | 0.17 |
| EPS Diluted Total Ops | 0.45 | 0.33 | 0.31 | 0.25 | 0.17 |
| EPS Diluted Continuous Ops | 0.45 | 0.34 | 0.31 | 0.25 | 0.17 |
| EBITDA(a) | $3,808,140 | $3,147,020 | $-1,066,560 | $2,139,550 | $1,846,150 |